publication . Article . 2018

Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα

Ying Sun; Ying Sun; Yu-jun Tan; Yu-jun Tan; Zhan-zhao Lu; Zhan-zhao Lu; Bing-bing Li; Bing-bing Li; Cheng-hong Sun; Cheng-hong Sun; ...
View all 25 authors
Open Access English
  • Published: 01 Mar 2018 Journal: Frontiers in Pharmacology (issn: 1663-9812, Copyright policy)
  • Publisher: Frontiers Media S.A.
Abstract
Burdock (Arctium lappa) is a popular vegetable in China and Japan that is consumed for its general health benefits. The principal active component of burdock is arctigenin, which shows a range of bioactivities in vivo and in vitro. Here, we investigated the potential anti-tumor effects of arctigenin using two human hepatocellular carcinoma (HCC) cell lines, HepG2 and Hep3B, and sought to elucidate its potential mechanisms of action. Our results showed that arctigenin treatment inhibited cell growth in both HepG2 and Hep3B cell lines (IC50 of 4.74 nM for HepG2 cells, and of 59.27 nM for Hep3B cells). In addition, migration, invasion, and colony formation by HepG2...
Read more
doi: 10.3389/fphar.2018.00268/full , 10.3389/fphar.2018.00268
pmid: 29636686
View all 4 identifiers
Subjects
Medical Subject Headings: digestive system diseases
free text keywords: arctigenin, C/EBPα, PPARα, gankyrin, hepatocellular carcinoma, Therapeutics. Pharmacology, RM1-950, Pharmacology (medical), Pharmacology, Original Research, Chemistry, Mechanism of action, medicine.symptom, medicine, Molecular biology, Cell growth, Carcinogenesis, medicine.disease_cause, biology.protein, biology, Luciferase, Cell culture, In vitro, chemistry.chemical_compound
Download fromView all 4 versions
Frontiers in Pharmacology
Article . 2018
Provider: DOAJ-Articles
Frontiers in Pharmacology
Article . 2018
Provider: Crossref
Frontiers in Pharmacology
Article
Provider: UnpayWall
Frontiers in Pharmacology
Article
Provider: Microsoft Academic Graph
View more
59 references, page 1 of 4

Bajaj M.Suraamornkul S.Hardies L. J.Glass L.Musi N.DeFronzo R. A. (2007). Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 50 1723–1731. 10.1007/s00125-007-0698-9 17520238 [OpenAIRE] [PubMed] [DOI]

Balanarasimha M.Davis A. M.Soman F. L.Rider S. D.Jr.Hostetler H. A. (2014). Ligand-regulated heterodimerization of peroxisome proliferator-activated receptor α with liver X receptor α. Biochemistry 53 2632–2643. 10.1021/bi401679y 24713062 [OpenAIRE] [PubMed] [DOI]

Brand E. J.Zhao Z. (2017). Cannabis in Chinese medicine: are some traditional indications referenced in ancient literature related to cannabinoids? Front. Pharmacol. 8:108. 10.3389/fphar.2017.00108 28344554 [OpenAIRE] [PubMed] [DOI]

Cast A.Valanejad L.Wright M.Nguyen P.Gupta A.Zhu L. (2017). C/EBPα-dependent pre-neoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer. Hepatology 10.1002/hep.29677 [Epub ahead of print]. 29159818 [OpenAIRE] [PubMed] [DOI]

Chapman A. M.McNaughton B. R. (2015). Synthetic proteins potently and selectively bind the oncoprotein gankyrin, modulate its interaction with S6 ATPase, and suppress gankyrin/MDM2-dependent ubiquitination of p53. ACS Chem. Biol. 10 1880–1886. 10.1021/acschembio.5b00201 25955581 [OpenAIRE] [PubMed] [DOI]

Chapman A. M.Rogers B. E.McNaughton B. R. (2014). Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase. Biochemistry 53 6857–6859. 10.1021/bi5012354 25343477 [OpenAIRE] [PubMed] [DOI]

Chattopadhyay A.O’Connor C. J.Zhang F.Galvagnion C.Galloway W. R.Tan Y. S. (2016). Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell. Sci. Rep. 6:23732. 10.1038/srep23732 27046077 [OpenAIRE] [PubMed] [DOI]

Crowe D. L.Chandraratna R. A. (2004). A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 6 R546–R555. 10.1186/bcr913 15318936 [OpenAIRE] [PubMed] [DOI]

Fleischer T.Su Y. C.Lin S. J. (2017). How do government regulations influence the ability to practice Chinese herbal medicine in western countries. J. Ethnopharmacol. 196 104–109. 10.1016/j.jep.2016.11.047 27915077 [OpenAIRE] [PubMed] [DOI]

Fritsche K. (2006). Fatty acids as modulators of the immune response. Annu. Rev. Nutr. 26 45–73. 10.1146/annurev.nutr.25.050304.092610 16848700 [OpenAIRE] [PubMed] [DOI]

Fu J.Chen Y.Cao J.Luo T.Qian Y. W.Yang W. (2011). p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology 53 181–192. 10.1002/hep.24015 21254169 [OpenAIRE] [PubMed] [DOI]

Georgiadi A.Kersten S. (2012). Mechanisms of gene regulation by fatty acids. Adv. Nutr. 3 127–134. 10.3945/an.111.001602 22516720 [OpenAIRE] [PubMed] [DOI]

Gu Y.Sun X. X.Ye J. M.He L.Yan S. S.Zhang H. H. (2012). Arctigenin alleviates ER stress via activating AMPK. Acta Pharmacol. Sin. 33 941–952. 10.1038/aps.2012.60 22705729 [OpenAIRE] [PubMed] [DOI]

Gupta R. A.Tan J.Krause W. F.Geraci M. W.Willson T. M.Dey S. K. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 97 13275–13280. 10.1073/pnas.97.24.13275 11087869 [OpenAIRE] [PubMed] [DOI]

Han L.Wang P.Sun Y.Liu S.Dai J. (2017). Anti-melanoma activities of haspin inhibitor CHR-6494 deployed as a single agent or in a synergistic combination with MEK inhibitor. J. Cancer 8 2933–2943. 10.7150/jca.20319 28928884 [OpenAIRE] [PubMed] [DOI]

59 references, page 1 of 4
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue